We investigated the long-term outcome of percutaneous @entity1068 injection ( @entity8681 ) in the treatment of @entity157 ( @entity157 ). A series of 184 @entity157 @entity1 received @entity8681 as the sole anticancer treatment over an 8-year period, December, 1987, to December, 1995. Ninety-four @entity1 had a single @entity5 < or = 3 cm, 50 @entity1 had a single lesion of 3.1-5 cm, and 40 @entity1 had multiple nodules (up to four) < or = 3 cm each. All @entity1 had @entity1575 , classified as @entity1 -Pugh class A in 127 cases and as @entity1 -Pugh class B in 57 cases. The treatment schedule included, for each lesion, 6-14 therapeutic sessions performed once or twice weekly. The total amount of @entity167 administered ranged 10 to 110 ml (mean: 36 ml). All @entity1 were followed after therapy with clinical examinations, laboratory tests, and imaging studies performed at regular time intervals. The follow-up period ranged 2 to 94 months (mean: 23.6 months). Overall survival rates by the Kaplan-Meier method were 67% at 3 years, 41% at 5 years, and 19% at 7 years. The survival rates of @entity1 with single lesion < or = 3 cm (78% at 3 years, 54% at 5 years, and 28% at 7 years, respectively) were significantly higher (p < .01) than those of the @entity1 with a single lesion of 3.1-5 cm (61% at 3 years, 32% at 5 years, and 16% at 7 years) or multiple lesions (51% at 3 years, 21% at 5 years, and 0% at 7 years). The survival of @entity1 -Pugh A @entity1 (79% at 3 years, 53% at 5 years, and 32% at 7 years) was significantly longer (p < .01) than that of @entity1 -Pugh B @entity1 (50% at 3 years, 28% at 5 years, and 8% at 7 years). A selected group of 70 @entity1 with @entity1 -Pugh A @entity82 and a single lesion < or = 3 cm had a 3-, 5-, and 7-year survival of 89%, 63% and 42%, respectively. During the follow-up, new lesions appeared in 93 @entity1 . The recurrence rates by the Kaplan-Meier method were 15% at 1 year, 34% at 2 years, 51% at 3 years, 67% at 4 years, 78% at 5 years, 88% at 6 years, and 94% at 7 years. The analysis of the survival curves of the treated @entity1 confirms the effectiveness of @entity8681 in the treatment of @entity157 . This therapeutic approach is particularly indicated for @entity1 with a single lesion 3 cm or less in greatest diameter, as in these cases the long-term results of @entity8681 are comparable to those reported in the best surgical series published in the literature.

[Percutaneous XXXX administration for hepatocarcinoma: long-term results].

@entity1 :: ('9606', 'Species') :: ['Child', 'patients'] @entity82 :: ('MESH:D005355', 'Disease') :: ['cirrhosis'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity167 :: ('CHEBI:16236', 'Chemical') :: ['alcohol'] @entity8681 :: ('CHEBI:53231', 'Chemical') :: ['PEI'] @entity1575 :: ('MESH:D008103', 'Disease') :: ['liver cirrhosis'] @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'hepatocellular carcinoma'] @entity1068 :: ('MESH:D000431', 'Chemical') :: ['ethanol']
@entity167 :: (CHEBI:16236,Chemical) :: ['alcohol']
